書籍詳細

序章 脳と栄養のクロストーク

P.22 掲載の参考文献

• 1) 本郷利憲, 広重 力(監修): 標準生理学第5版. 医学書院, 2000.

• 2) 嶋津 孝, 斉藤昌之(編): 神経と代謝調節. 朝倉書店, 1988.

• 3) 嶋津 孝: 脳の中の視床下部, ブレーン出版, 1999.

• 4) 中川八郎: ブレインサイエンスシリーズ1 脳の栄養. 共立出版, 1988.

• 5) 大村 裕, 坂田利家: ブレインサイエンスシリーズ9 脳と食欲, 共立出版, 1999.

• 6) Schwartz M.W., Woods S.C., Prote Jr D. et al:Central nervous system control of food intake. Nature 2000; 404; 661-671.

第1章 食事アミノ酸と脳機能

P.59 掲載の参考文献

• 1) 鳥居邦夫: 嗜好形成とその変化. 臨床栄養 / 臨時増刊号 1990; 76; 608-617.

• 2) Torii K.:Effects of dietary protein on the taste preference for amino acids in rats. In:Interaction of the chemical senses with nutrition, Kare M.R. et al (ed), Academic Press, New York, 1986, p 45-69.

• 3) Mori M., Kawada T., Torii K. et al:Taste preference and protein nutrition and L-amino acid homeostasis in male Sprague-Dawley rats. Physiol Behav 1991; 49;987-995.
  pubmed

• 4) Torii K., Mimura T., Yugari Y.:Biochemical mechanism of umami taste perception and effect of dietary protein on the taste preference for amino acids and sodium chloride in rats. In Umami:A basic taste, Kawamura Y., Kare M.R. et al (ed), Marcel Dekker, New York, 1987, p.513-564.

• 5) Rogers Q. R., Harper A.E.:Selection of a solution containing histidine by rats fed a histidine-imbalanced diet. J Comp Physiol Psychol 1970; 72; 66-71.

• 6) Panksepp J., Booth D.A.:Decreased feeding after injenction of amino acids into the hypothalamus. Nature 1971; 233; 341-342.

• 7) Gietzen D.W., Erecius L.F., Rogers Q.R.:Neurochemical changes after imbalanced diet to amino acid deficiency in rats, J Nutri 1998; 128; 771-81.

• 8) Wayner M. J., Ono T., De Young A. et al:Effects of essential amino acids on central neurons. Pharmacol Biochem Behav 1975; 3 (Suppl.1); 85-90.

• 9) Ono T., Tabuchi E., Torii K. et al; Rat hypothalamic neuron responses during amino acid ingestion and to iontophoretic amino acid. Chem Senses 1990; 15; 392.

• 10) Torii K., Niijima A.:Effect of lysine on afferent activity of the physiological behaviour hepatic branch of the vagus nerve in hormal and L-lysine deficient rats. Physiol Behav 2001; 72; 685-690.

• 11) Hawkins R.L., Inoue M., Torii K. et al:Lysine deficient diet and lysine replacement affect food direted operant behavior. Physiol Behav 1994; 56; 1061-1068.

• 12) Torii K., Hanai K., Oosawa M. et al:Activin A:Serum lecels and immunohistochemical brain localization in rats given diets deficient in L-lysine or protein. Physiol Behav 1993; 54; 459-466.
  pubmed

• 13) Vale W., Rivier J., Vaughan J.:Purificaiton and characterization of an FSHReleasing protein from porcine ovarian follicular fuid. Nature 1986; 321; 776-779.

• 14) Hashimoto M., Kondoh S., Sakurai S. et al:Activin/EDF as an inhibitor of neural differentiation. Biochem. Biophys Res Commun 1990; 173; 193-200.

• 15) 上野直人: アクチビンの構造と生理機能. 実験医学 1992; 10; 104-108

• 16) Hawkins R. L., Inoue M., Torii K. et al:Effect of inhibin, follistatin, or activin infusion into the lateral hypothalamus on operant behavior of rats fed lysine deficient deit. Brain Res., in print.

• 17) Tabuchi E., Ono Torii K. et al:Amino acid and NaCl appetite, and LHA neuron responses of lysine-deficient rat. Physiol Behav 1991; 49; 951-964.
  pubmed

• 18) Smriga M., Mori M. Torii K.:Circadian release of hypothalamic norepinephrine in rats in vivo is depressed during early L-lysine deficiency. J Nutri 2000; 130; 1641-1643.

• 19) 鳥居邦夫: おいしさの科学. 調理とおいしさの科学 (島田淳子, 下村道子編), 朝倉書店, 1993, p53-97.

• 20) 鳥居邦夫: 食行動における脳の働き -栄養と嗜好-. 健康の科学シリーズ2 (食と健康監修, 武藤泰敏編), 学会センター関西, 1996, p75-124.

第2章 ビタミンによる脳機能制御

P.89 掲載の参考文献

• 1) Chiang M.Y., Misner D., Kempermann G. et al:An essential role for retinoid receptors RARbeta and RXRgamma in long-term potentiation and depression Neuron 1998; 21; 1353-61.
  pubmed

• 2) Misner D.L., Jacobs S., Shimizu Y. et al:Vitamin A deprivation results in reversible loss of hippocampal long-term synaptic plasticity. Proc Natl Acad Sci USA 2001; 98; 11714-11719.
  pubmed

• 3) de Urquiza A.M., Liu S., Sjoberg M. et al:Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 2000; 290; 2140-2144.
  pubmed

• 4) Krezel W., Ghyselinck N., Samad T.A. et al:Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. Science 1998; 279; 863-867.
  pubmed

• 5) Kida S., Josselyn S., Pe_a de Ortiz S. et al:CREB required for the stability of new and reactivated fear memory. Nat Neurosci 2002; 5; 348-355.

• 6) 喜田聡, 内田周作, 舛重正一: レチノイン酸による情動行動制御. 細胞 2002; 34; 12-15.

• 7) King D.P., Zhao Y., Sangoram A.M. et al:Positional cloning of the mouse circadian clock gene. Cell 1997; 89; 641-653.
  pubmed

• 8) McNamara P., Seo S.P., Rudic R.D. et al:Regulation of CLOCK and MOP4 by nuclear hormone receptors in the vasculature:a humoral mechanism to reset a peripheral clock. Cell 2001; 105; 877-889.

• 9) Zheng B., Albrecht U., Kaasik K. et al:Nonredundant roles of the mPer1 and mPer2 genes in the mammalian circadian clock. Cell 2001; 105; 683-694.
  pubmed

• 10) Silva A., Kogan J., Kida S. et al:CREB and memory, Annu Rev Neurosci 1998; 21; 127-148.
  pubmed

• 11) Marsicano G., Wotjak C.T., Azad S.C. et al:The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418; 530-534.
  pubmed

• 12) Sotiriou S., Gispert S., Cheng J. et al:Ascorbic-acid transporter Slc23a1 is essential for vitamin C transport into the brain and for perinatal survival. Nat Med 2002; 8; 514-517.
  pubmed

• 13) Ouahchi K., Arita M., Kayden H. et al:Ataxia with isolated vitamin E deficiency is caused by mutations in the alpha-tocopherol transfer protein. Nat Genet 1995; 9; 141-145.
  pubmed

• 14) Gotoda T., Arita M., Arai H. et al:Adult-onset spinocerebellar dysfunction caused by a mutation in the gene for the alpha-tocopherol-transfer protein. N Engl J Med 1995; 333; 1313-1318.
  pubmed

• 15) Yokota T., Igarashi K., Uchihara T. et al:Delayed-onset ataxia in mice lacking alpha-tocopherol transfer protein:model for neuronal degeneration caused by chronic oxidative stress. Proc Natl Acad Sci USA 2001; 98; 15185-15190.
  pubmed

第3章 行動の分子基盤を求めて ─非栄養素による脳内物質代謝と機能の変化─ (緑茶, キノコ, 香辛料などに含まれる非栄養素と脳との関連)

P.108 掲載の参考文献

• 1) Kimura R., Murata T.:Effect of theanine on norepinephrine and serotonin levels in rat brain. Chem Pharm Bull 1986; 34; 3053-3057.
  pubmed

• 2) Terashima T., Takido J., Yokogoshi H.:Time-dependent changes of amino acids in the serum, liver, brain and urine of rats administered with theanine. Biosci Biotechnol Biochem 1999; 63; 615-618.
  pubmed

• 3) Yokogoshi H., Kobayashi M., Mochizuki M. et al:Effect of theanine, γ-glutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats. Neurochem Res 1998; 23; 667-673.

• 4) Essman W. B.:Nutrients and Brain Function, Karger Pub., New York, 1987.

• 5) Yokogoshi H., Mochiznki M., Saitoh K.:Theanine-induced reduction of brain serotonin concentration in rats. Biosci Biotechnol Biochem 1998; 62; 816-817.

• 6) Yokogoshi H.,Nomura M.:Effect of amino acid supplementation to a low protein diet on brain neurotransmitters and memory-learning ability of rats. Physiology Behav 1991; 50; 1227-1232.
  pubmed

• 7) Yokogoshi H., Kato Y.et al:Reduction effect of theanine on blood pressure and brain 5-hydroxyindoles in spontaneously hypertensive rats. Biosci Biotechnol Biochem 1995; 59; 615-618.
  pubmed

• 8) Yokogoshi H, Kobayashi M.:Hypotensive effect of γ-glutamylmethylamide in spontaneously hypertensive rats. Life Sci 1998; 62; 1065-1068.

• 9) Sato T., Takeuchi A., Ishida T. et al:Antihypertensive effect of an aqueous extract from fruit body of Mycoleptodonoides aitchisonii in spontaneously hypertensive rats. Oyo Yakuri/Pharmacometrics 2001; 61 (1); 177-183.

• 10) Sakamoto Y., Takeuchi A., Sato T. et al:Identification of antihypertensive substance in an aqueous extract from fruit body of Mycoleptodonoides aitchisonii. Oyo Yakuri/Pharmacometrics 2001; 61(4/5); 221-229.

• 11) Large H.L., Bodary S.C., Clegg D.O. et al:Nerve growth factor gene expression in the developing rat brain. Science 1986; 234; 352-355.

• 12) Furukawa Y., Furukawa S., Satoyoshi E. et al:Catecholamines induce an increase in nerve growth factor content in the medium of mouse L-M cells. J Biol Chem 1986; 261 (13); 6063-6047.

• 13) Furukawa Y., Furukawa S., Ikeda F. et al:Aliphatic side chain of catecholamine potentiates the stimulatory effect of the catechol part on the systhesis of nerve growth factor. FEBS Lett 1986; 208; 258-262.

• 14) Furukawa Y., Tomioka N., Sato W. et al:Catecholamines increase nerve growth factor mRNA content in both mouse astroglial cells and fibroblast cells. FEBS Lett 1989; 247; 463-467.
  pubmed

• 15) Kawagishi H., Ando M., Shinba K. et al:Chromans, hericenones F, G and H from the mushroom Hericium erinaceum. Phytochemistry 1993; 32; 175-178.

• 16) Kawagishi H., Shimada A., Shirai R. et al:Erinacines A, B and C, strong stimulators of nerve growth factor NGF-synthesis, from the mycelia of Hericium erinaceum. Tetrahed Lett 1994; 35 (10); 1569-1572.

• 17) Kittner H., Krugel U., Poelchen W. et al:P2 receptor-mediated activation of noradrenergic and dopaminergic neurons in the rat brain. Progr Brain Res 1999; 120; 223-235.

• 18) Krugel U., Kittner H., Illes P.:Adenosine 5-triphosphate-induced dopamine release in the rat nucleus accumbens in vivo. Neurosci Lett 1999; 265; 49-52.
  pubmed

• 19) Krugel U., Kittner H., Franke H. et al:Stimulation of P2 receptors in the ventral tegmental area enhances dopaminergic mechanisms in vivo. Neuropharmacology 2001; 40; 1084-1093.
  pubmed

• 20) Zhang Y-X., Yamashita H., Ohshita T. et al:ATP increases extracellular dopamine level through stimulation of P2Y purinoceptors in the rat striatum. Brain Research 1995; 691; 205-212.
  pubmed

• 21) Pardridge W.M., Yoshikawa T., Kang Y.S. et al:Blood-brain barrier transport and brain metabolism of adenosine and adenosine analogs. J Pharmacol Exp Theraps 1994; 268 (1); 14-18.

• 22) Okada M., Mizuno K., Kaneko S.:Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum. Neurosci Lett 1996; 212; 53-56.
  pubmed

• 23) Thoenen H., Barde Y.A., Edgar D. et al:Mechanism of action and possible sites of synthesis of nerve growth factor. Prog Brain Research 1979; 51; 95-107.
  pubmed

• 24) Thoenen H., Barde Y.A.:Physiology of nerve growth factor. Physiol Revi 1980; 60 (4); 1284-1335.

• 25) Maisonpierre P.C., Belluscio L., Friedman B. et al:NT-3, BDNF, and NGF in the developing rat nervous system:Parallel as well as reciprocal patterns of expression. Neuron 1990; 5; 501-509.
  pubmed

• 26) Xia Y.X., Ikeda T., Xia X.Y. et al:Differential neurotrophin levels in cerebrospinal fluid and their changes during development in newborn rat. Neurosci Lett 2001; 280; 220-222.

• 27) Davies A. M.:Neurotrophin switching:where does it stand? Cur Opinion Neurobiol 1997; 7 (1); 110-118.

• 28) Hyman C., Hofer M., Barde Y.A. et al:BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991; 350; 230-232.
  pubmed

• 29) Knusel B., Winslow J. W., Rosenthal A. et al:Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3. Proc Nat Acad Sci U States A 1991; 88 (3); 961-965.
  pubmed

• 30) Watanabe T., Kawada T.,Iwai K.:Enhancement by capsaicin of metabolism in rats through secretion of catecholamine from adrenal medulla. Agric Biol Chem 1987; 51; 75.

• 31) Saria A., Skofitsch G., Lembeck F.:Distribution of capsaicin in rat tissue after systemic administration. J Pharm Pharmacol 1982; 34; 273-275.
  pubmed

• 32) Kim K-M., Kawada T., Ishihara K. et al:Swimming capacity is increased by oral administration of a nonpungent capsaicin analog, stearoyl vanillylamide, in mice. J Nutr 1998;128 11;1978-1983.
  pubmed

• 33) Dawbarn D., Harmar A.J., Pycock C.J.:Intranigral injection of capsaicin enhances motor activity and depletes nigral 5-hydroxytryptamine but not substance P. Neuropharmacol 1981; 20; 341-346.
  pubmed

• 34) Sasamura T., Sasaki M., Tohda C. et al:Existence of capsaicin-sensitive glutamatergic terminals in rat hypothalamus. Neuro Report 1998; 9; 2045-2048.

• 35) Sasamura T., Kuraishi Y.:Peripheral and central actions of capsaicin and VR1 receptor. Jpn J Pharmacol 1999; 80; 275-280.
  pubmed

• 36) 森 寿, 真鍋俊也, 渡辺雅彦ほか: 脳神経化学イラストレイテッド. 羊土社, 2000, p186-192.

• 37) Ueda M., Kuraishi Y., Satoh M.:Detection of capsaicin-evoked release of glutamate from spinal dorsal horn slices of rat with on-line monitoring system. Neurosci Lett 1993; 155; 179-182.
  pubmed

第4章 脳内ヒスタミンとエネルギー代謝

P.135 掲載の参考文献

• 1) Zhang Y., Proenca R., Maffei M. et al:Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372; 425-431.
  pubmed

• 2) Huang Q., Rivest R., Richard D.:Effects of leptin on corticotropin-releasing factor (CRF) synthesis and CRF neuron activation in the paraventricular hypothalamic nucleus of obese (ob/ob) mice. Endocrinology 1998; 139; 1524-1532.
  pubmed

• 3) Marsh D. J., Hollopeter G., Huszar D. et al:Response of melanocortin-4 receptordeficient mice to anorectic and orexigenic peptides. Nat Genet 1999; 21:119-122.
  pubmed

• 4) Sahu A.:Leptin decreased food intake induced by melanin-concentrating hormone (MCH), galanin (GAL) and neuropeptide Y (NPY) in the rat. Endocrinology 1998; 139; 4739-4742.
  pubmed

• 5) Mantzoros C. S., Moschos S. J.:Leptin:In search of role(s) in human physiology and pathophysiology. Clin Endocrinol 1998; 49; 551-567.
  pubmed

• 6) Schrauwen P., Walder K., Ravussin E.:Human uncoupling proteins and obesity. Obes Res 1999; 7(1); 97-105.
  pubmed

• 7) Hosoda K., Masuzaki H., Ogawa Y. et al:Development of radioimmunoassay for human leptin. Biochem Biophys Res Commun 1996; 221; 234-239.
  pubmed

• 8) 日高周次, 小川佳宏, 海老原健ほか:肥満におけるレプチン抵抗性の病態とその意義. 日本臨床 2001; 59(3);472-480.
  Medical*Online

• 9) Schwartz M.W., Peskind E., Raskind M. et al:Cerebrospinal fluid levels:Relationship to plasma levels and to adiposity in humans. Nat Med 1996; 2; 589-593.
  pubmed

• 10) Sakata T., Ookuma K., Fukagawa K. et al:Blockade of the histamine H1-receptor in the rat ventromedial hypothalamus and feeding elicitation. Brain Res 1988; 16; 403-40.

• 11) Panula P., Pirvola U., Auvinen S. et al.:Histmaine-immunoreactive nerve fibers in the rat brain. Neuroscience 1989; 28 (3); 585-610.

• 12) Tohyama M., Tamiya R., Inagaki N. et al:In Histaminergic Neurons:Morphology and Function, Watanabe T and Wada H.(ed), CRC Press, Boca Raton, 1991 p107-126.

• 13) Sakata T.:A very-low-calorie conventional Japanese diet:its implications for prevention of obesity. Obes Res 1995; 3 (Suppl.2); 233s-239s.

• 14) Arrang J-M., Garbarg M., Schwartz J-C.:Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983; 302; 832-837.
  pubmed

• 15) Arrang J-M., Garbarg M., Lancelot J-C. et al:Highly potent and selective ligands for histamine H3-receptors. Nature 1987; 327; 117-123.
  pubmed

• 16) Ookuma K., Sakata T., Fukagawa K. et al:Neuronal histamine in the hypothalamus suppresses food intake in rats. Brain Res 1993; 628; 235-242.
  pubmed

• 17) Tsuda K., Yoshimatsu Y., Niijima A. et al:Hypothalamic histamine neurons activate lipolysis in rat adipose tissue. Exp Biol Med 2002; 227; 208-213.

• 18) 坂田利家, 吉松博信, 正木孝幸: 中枢性摂食異常症における神経ヒスタミン機能のH1受容体欠損動物による解析. 厚生科学研究費補助金分担研究報告書, 2000.

• 19) Yoshimatsu H., Itateyama E., Kondou S. et al:Hypothalamic neuronal histamine as a target of leptin in feeding behavior. Diabetes 1999; 48; 2286-2291.
  pubmed

• 20) 坂田利家, 吉松博信, 桶田俊光ほか: 糖尿病における高次脳機能障害の解析と中枢神経ヒスタミンの役割. 平成8年度科学研究補助金研究成果報告書, 1998.

• 21) 中島 滋, 田中 香, 濱田 稔ほか: 瀬戸内海浜地区の女性におけるエネルギー摂取量とヒスチジン摂取量との相関. 肥満研究 2001; 7(3) ; 276-282.
  Medical*Online

第5章 胃ペプチドグレリンと食行動

P.151 掲載の参考文献

• 1) Kojima M., Hosoda H., Date Y. et al:Ghrelin is a novel growth hormone releasing acylated peptide from stomach. Nature 1999; 402; 656-660.

• 2) Spiegelman B.M., Flier J.S.:Obesity and the regulation of energy balance. Cell 2001; 104; 531-543.
  pubmed

• 3) Ahima R.S., Osei S.Y.:Molecular regulation of eating behavior:new insights and prospects for therapeutic strategies. Trends Mol Med 2001; 7; 205-213.
  pubmed

• 4) Schwartz M.W., Woods S.C., Porte D. Jr. et al:Central nervous system control of food intake. Nature 2000; 404; 661-671.
  pubmed

• 5) Momany F.A., Bowers C.Y., Reynolds G.A. et al:Design, synthesis, and biological activity of peptides which release growth hormone in vitro. Endocrinology 1981; 108; 31-39.
  pubmed

• 6) Smith R.G., Van der Ploeg L.H., Howard A.D. et al:Peptidomimetic regulation of growth hormone secretion. Endocr Rev 1997; 18; 621-645.
  pubmed

• 7) Chapman I.M., Bach M.A., Van Cauter E. et al:Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab 1996; 81; 4249-4257.
  pubmed

• 8) Camanni F., Ghigo E., Arvat E.:Growth hormone-releasing peptides and their analogs. Front Neuroendocrinol 1998; 19; 47-72.

• 9) Casanueva F.F., Dieguez C.:Growth hormone secretagogues:Physiological role and clinical utility. Trends Endocrinol Metab 1999; 10; 30-38.
  pubmed

• 10) Smith R.G., Cheng K., Schoen W.R. et al:A nonpeptidyl growth hormone secretagogue. Science 1993; 260; 1640-1643.
  pubmed

• 11) Pong S.S., Chaung L.Y., Dean D.C. et al:Identifi cation of a new G-protein-linked receptor for growth hormone secretagogues. Mol Endocrinol 1996; 10; 7-61.

• 12) Hosoda H., Kojima M., Matsuo H. et al:Purification and characterization of rat des-Gln14-ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor. J Biol Chem 2000;275;21995-22000.
  pubmed

• 13) Kaiya H., Kojima M., Hosoda H. et al:Bullfrog ghrelin is modifi ed by n-octanoic acid at its third threonine residue. J Biol Chem 2001; 276; 40441-40448.

• 14) Kaiya H., Van Der Geyten S., Kojima M, et al:Chicken ghrelin:purification, DNA cloning, and biological activity. Endocrinology 2002; 143; 3454-3463.
  pubmed

• 15) Unniappan S., Lin X., Cervini L. et al:Goldfish ghrelin:molecular characterization of the complementary deoxyribonucleic acid, partial gene structure and evidence for its stimulatory role in food intake. Endocrinology 2002; 143; 4143-4146.
  pubmed

• 16) Date Y., Kojima M., Hosoda H. et al:Ghrelin, a novel growth-hormonereleasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000; 141; 4255-4261.

• 17) Hayashida T., Nakahara K., Mondal M.S. et al:Ghrelin in neonatal rats:distribution in stomach and its possible role. J Endocrinol 2002; 173; 239-245.

• 18) Lu S., Guan JL., Wang Q.P. et al:Immunocytochemical observation of ghrelincontaining neurons in the rat arcuate nucleus. Neurosci Lett 2002; 321; 157-160.
  pubmed

• 19) McKee K.K., Palyha O.C., Feighner S.D. et al:Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors. Mol Endocrinol 2002; 11; 415-123.

• 20) Petersenn S., Rasch A.C., Penshorn M. et al:Genomic structure and transcriptional regulation of the human growth hormone secretagogue receptor. Endocrinology 2001; 142; 2649-2659.
  pubmed

• 21) Kaji H., Kishimoto M., Kirimura T. et al:Hormonal regulation of the human ghrelin receptor gene transcription. Biochem Biophys Res Commun 2001; 284; 660-666.
  pubmed

• 22) Nakazato M., Murakami N., Date Y. et al:A role for ghrelin in the central regulation of feeding. Nature 2001; 409; 194-198.
  pubmed

• 23) Tschop M., Smiley D.L., Heiman M.L.:Ghrelin induces adiposity in rodents. Nature 2000; 407; 908-913.
  pubmed

• 24) Wren A.M, Seal L.J, Cohen M.A. et al:Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86; 5992-5995.
  pubmed

• 25) Stanley B.G., Kyrkouli S.E., Lampert S. et al:Neuropeptide Y chronically injected into the hypothalamus:a powerful neurochemical inducer of hyperphagia and obesity. Peptides 1986;7;1189-1192.
  pubmed

• 26) Billington C.J., Briggs JE., Grace M. et al:Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism. Am J Physiol 1991; 260; R321-R327.
  pubmed

• 27) Shutter J.R., Graham M., Kinsey A.C. et al:Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes Dev 1997; 11; 593-602.
  pubmed

• 28) Sakurai T., Amemiya A., Ishii M. et al:Orexins and orexin receptors:a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92; 573-585.

• 29) Qu D., Ludwig D.S., Gammeltoft S. et al:A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 1996; 380; 243-247.

• 30) Kalra S.P., Dube M.G., Pu S. et al:Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 1999;20;68-100.
  pubmed

• 31) Zhang Y., Proenca R., Maffei M. et al:Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372; 425-432.
  pubmed

• 32) Elmquist J.K.:Anatomic basis of leptin action in the hypothalamus. Front Horm Res 2000; 26; 21-41.
  pubmed

• 33) Hahn T.M., Breininger JF., Baskin D.G. et al:Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat Neurosci 1998; 1; 271-272.
  pubmed

• 34) Willesen MG., Kristensen P., Romer J.:Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology 1999; 70; 306-316.
  pubmed

• 35) Sagar SM., Sharp FR., Curran T.:Expression of c-fos protein in brain:metabolic mapping at the cellular level. Science 1988; 240; 1328-1331.
  pubmed

• 36) Fan W., Boston B.A., Kesterson R.A. et al:Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997; 385; 165-168.
  pubmed

• 37) Kristensen P., Judge ME., Thim L. et al:Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 1998; 393; 72-76.
  pubmed

• 38) Marks D.L., Cone R.D.:Central melanocortins and the regulation of weight during acute and chronic disease. Recent Prog Horm Res 2001; 56; 359-375.
  pubmed

• 39) Mountjoy K.G., Mortrud M.T., Low M.J. et al:Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol 1994; 8; 1298-1308.
  pubmed

• 40) Lin L., Faraco J., Li R. et al:The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98; 365-376.
  pubmed

• 41) Chemelli R.M., Willie J.T., Sinton C.M. et al:Narcolepsy in orexin knockout mice:molecular genetics of sleep regulation. Cell 1999; 98; 437-451.
  pubmed

• 42) Lu S., Guan J.L., Wang Q.P. et al:Immunocytochemical observation of ghrelincontaining neurons in the rat arcuate nucleus. Neurosci Lett 2001; 321; 157-160.

• 43) Horvath T.L., Diano S., van den Pol A.N.:Synaptic interaction between hypocretin (orexin) and neuropeptide Y cells in the rodent and primate hypothalamus:a novel circuit implicated in metabolic and endocrine regulations. J Neurosci 1999; 19; 1072-1087.

• 44) Date Y., Murakami N., Toshinai K. et al:The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion. Gastroenterology 2002; 123; 1120-1128.
  pubmed

• 45) Wei J.Y., Wang Y.H.:Effect of CCK pretreatment on the CCK sensitivity of rat polymodal gastric vagal afferent in vitro. Am J Physiol Endocrinol Metab 2000; 279; E695-E706.
  pubmed

• 46) Shiiya T., Nakazato M., Mizuta M. et al:Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002; 87; 240-244.
  pubmed

• 47) Cummings D.E., Purnell J.Q., Frayo R.S. et al:A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50; 1714-1719.
  pubmed

• 48) Tschop M., Wawarta R., Riepl R.L. et al Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest 2001; 24; RC19-21.

• 49) Toshinai K., Mondal M.S., Nakazato M. et al:Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochem Biophys Res Commun 2001; 281; 1220-1225.
  pubmed

• 50) Hayashida T., Murakami K., Mogi K. et al:Ghrelin in domestic animals:distribution in stomach and its possible role. Domest Anim Endocrinol 2001; 21; 17-24.
  pubmed

• 51) Norrelund H., Hansen T.K., Orskov H. et al:Ghrelin immunoreactivity in human plasma is suppressed by somatostatin. Clin Endocrinol 2002; 57; 539-546.
  pubmed

• 52) Date Y., Nakazato M., Hashiguchi S. et al:Ghrelin is present in pancreatic a-cells of humans and rats and stimulates insulin secretion. Diabetes 2002; 51; 124-129.

• 53) Murata M., Okimura Y., Iida K. et al:Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J Biol Chem 2002; 277; 5667-5674.

• 54) Date Y., Nakazato M., Murakami N. et al:Ghrelin acts in the central nervous system to stimulate gastric acid secretion. Biochem Biophys Res Commun 2001; 280;904-907.
  pubmed

• 55) Masuda Y., Tanaka T., Inomata N. et al:Ghrelin stimulates gastric acid secretion and motility in rats. Biochem Biophys Res Commun 2000; 276; 905-908.
  pubmed

• 56) Nagaya N., Kojima M., Uematsu M. et al:Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 2001; 280; R1483-R1487.
  pubmed

• 57) Nagaya N., Uematsu M., Kojima M. et al:Elevated circulating level of ghrelin in cachexia associated with chronic heart failure:relationships between ghrelin and anabolic/catabolic factors. Circulation 2001; 104; 2034-2038.
  pubmed

• 58) Nagaya N., Uematsu M., Kojima M. et al:Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001; 104; 1430-1435.
  pubmed

• 59) Nagaya N., Miyatake K., Uematsu M. et al:Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab 2001; 86; 5854-5849

第6章 エネルギー消費の自律的調節と食事・栄養

P.179 掲載の参考文献

• 1) Klingenberg M., Huang S-G.:Structure and function of the uncoupling protein from brown adipose tissue. Biochim Biophys Acta 1999; 1415; 271-296.
  pubmed

• 2) Silva J.E., Rabelo R.:Regulation of the uncoupling protein gene expression. Eur J Endocrinol 1997; 136; 251-264.
  pubmed

• 3) Ricquier D., Bouillaud F.:The uncoupling protein homologues:UCP1, UCP2, UCP3, StUCP and At UCP. Biochem J 2000; 345; 161-179 (2000)
  pubmed

• 4) Stuart J.A., Cadenas S., Jekabsons M.B. et al:Mitochondrial proton leak and the uncoupling protein 1 homologues. Biochim Biophys Acta 2001; 1504; 144-158.
  pubmed

• 5) Saito M., Minokoshi Y., Shimazu T.:Brown adipose tissue after ventromedial hypothalamic lesions in rats. Am J Physiol 1985; 248; E20-E25.
  pubmed

• 6) Shimizu Y., Nikami H., Saito M.:Sympathetic activation of glucose utilization in brown adipose tissue in rats. J Biochem 1991; 110; 688-692.
  pubmed

• 7) Minokoshi Y., Saito M., Shimazu T.:Sympathetic activation of lipid synthesis in brown adipose tissue in the rat. J Physiol 1998; 398; 361-370.

• 8) Minokoshi Y., Saito M., Shimazu T.:Adrenergic blockade paradoxically increases lipogenic response of brown adipose tissue to sympathetic nerve stimulation. Neurosci Lett 1990; 109; 341-346.
  pubmed

• 9) Minokoshi Y., Saito M., Shimazu T.:Sympathetic denervation impairs responses of brown adipose tissue to VMH stimulation. Am J Physiol 1986; 251; R1005-R1008.
  pubmed

• 10) Shimazu T., Takahashi A.:Stimulation of hypothalamic nuclei has differential effects on lipid synthesis in brown and white adipose tissue. Nature 286; 62-63.

• 11) Sudo M., Minokoshi Y., Shimazu T.:Ventromedial hypothalamic stimulation enhances peripheral glucose uptake in anesthetized rats. Am J Physiol 1991; 261;E298-303.
  pubmed

• 12) Saito M., Minokoshi Y., Shimazu T.:Ventromedial hypothalamic stimulation accelerates norepinephrine turnover in brown adipose tissue of rats. Life Sci 1987; 41; 193-197.
  pubmed

• 13) Saito M., Minokoshi Y., Shimazu T.:Accelerated norepinephrine turnover in peripheral tissues after vetromedial hypothalamic stimulation in rats. Brain Res 1989; 481; 298-303.

• 14) Niijima A., Jeanrenaud F.R., Jeanrenaud B.:Role of ventromedial hypothalamus on sympathetic efferents of brown adipose tissue. Am J Physiol 1984; 247; R650-R654.

• 15) Nikami H., Shimizu Y., Saito M. et al:Cold exposure increases glucose utilization and glucose transporter expression in brown adipose tissue. Biochem Biophys Res Commun 1992; 185; 1078-1082.
  pubmed

• 16) Shimizu Y., Nikami H., Saito M. et al:Increased expression of glucose transporter GLUT-4 in brown adipose tissue of fasted rats after cold exposure. Am J Physiol 1993;264;E 890-E 895.

• 17) Tsukazaki K., Nikami H.,Saito M.et al:Chronic administration of??-adrenergic agonists can mimic the stimulative effect of cold exposure on protein synthesis in rat brown adipose tissue. J Biochem 1995; 117; 96-100.
  pubmed

• 18) Asano A., Morimatsu M., Saito M.et al:Adrenergic activation of vascular endothelial growth factor mRNA expression in rat brown adipose tissue:implication in cold-induced angiogenesis. Biochem J 1997; 328; 179-183.
  pubmed

• 19) Shimizu Y., Saito M.:Activation of brown adipose tissue thermogenesis in recovery from anesthetic hypothermia in rats. Am J Physiol 1991; 261; R301-R304.
  pubmed

• 20) Jansky L.:Humoral thermogenesis and its role in maintaining energy balance. Physiol Rev 1995; 75; 237-259.
  pubmed

• 21) Saito M., Shimazu T.:Decreased rate of fatty acid synthesis in brown adipose tissue of hypothalamic obese rats. FEBS Lett 1984; 166; 151-154.
  pubmed

• 22) Lowell B.B., S-Susulic V., Hamann A. et al:Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature 1993; 366;740-742

• 23) Kopecky J., Clarke G., Enerback S. et al:Expression of the mitochondrial uncoupling protein gene from the aP2 gene promoter prevents genetic obesity. J Clin Invest 1995; 96; 2914-2923.

• 24) Enerback S., Jacobsson A., Simpson E.M. et al:Mice lacking mitochondrial uncoupling protein are cold-sensitive but not obese. Nature 1997; 387; 90-94
  pubmed

• 25) 山下均, 紺谷靖英, 王幼学ほか: 加齢にともなう肥満の進展とUCP1の役割. 肥満研究 2002; 8; 131-135.

• 26) Nagase I., Yoshida T., Kumamoto K. et al:Expression of uncoupling protein in skeletal muscle and white fat of obese mice treated with thermogenic β3-adrenergic agonist. J Clin Invest 1996; 97; 2898-2904.

• 27) Umekawa T., Yoshida T., Sakane N. et al:Anti-obesity and anti-diabetic effecs of CL316,243, a highly specific β3-adrenoceptor agonist, in Otsuka Long-Evans Tokushima Fatty rats:induction of uncoupling protein and activation of glucose transporter 4 in white fat. Eur J Endocrinol 1997; 136; 429-437.

• 28) Yoshida T., Umekawa T., Kumamoto K. et al:β3-Adrenergic agonist induces a functionally active uncoupling protein in fat and slo-twitch muscle fibers. Am J Physiol 1998;274;E469-E475.

• 29) Sasaki N., Uchida E., Niiyama M. et al; Anti-obesity effects of selective agonists to β3-adrenergic receptor in dogs. II. Recruitment of thermogenic brown adipocytes and reduction of adiposity after chronic treatment with a β3-adrenergic agonist. J Vet Med Sci 1998; 60; 465-469.

• 30) Diamond P., Brondel L., LeBlanc J.:Palatability and postprandial thermogenesis in dogs. Am J Physiol 1985; 248; E75-E79.
  pubmed

• 31) Diamond P., LeBlanc J.:Role of autonomic nervous system in postprandial thermogenesis in dogs. Am J Physiol 1987; 252;E719-E726.
  pubmed

• 32) LeBlanc J., Cabanac M., Samson P.:Reduced postprandial heat production with gavage as compared with meal feeding in human subjects. Am J Physiol 1984; 246;E95-E101.
  pubmed

• 33) LeBlanc J., Brondel L.:Role of palatability on meal-induced thermogenesis in human subjects. Am J Physiol 1985;248; E333-E336.
  pubmed

• 34) Saito M., Minokoshi Y., Shimazu T.:Metabolic and sympathetic nerve activities of brown adipose tissue in tube-fed rats. Am J Physiol 21989; 57;E374-E378.

• 35) Minokoshi Y., Kim Y-B., Peroni O.D. et al:Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002; 415; 339-343.
  pubmed

• 36) Lowell B.B., Spiegelman B.M.:Towards a molecular understanding of adaptive thermogenesis. Nature 2000; 404; 652-660

• 37) Nagase I., Yoshida S., Canas X. et al:Up-regulation of uncoupling protein 3 by thyroid hormone, peroxisome proliferator-activated receptor ligands and 9-cis retinoic acid in L6 myotubes. FEBS Lett 1999; 461; 319-322.
  pubmed

• 38) Nagase I., Yoshida T., Saito M.:Up-regulation of uncoupling proteins by βadrenergic stimulation in L6 myotubes. FEBS Lett 2001; 494; 175-180.

• 39) Kelly G.D.:Conjugated linoleic acid:a review. Altern Med Rev 2001; 6; 367-382.

• 40) Tsuboyama-Kasaoka N., Takahashi M., Tanemura K. et al:Conjugated linoleic acid supplementation reduces adipose tissue by apoptosis and develops lipodystrophy in mice. Diabetes 2000; 49; 1534-1542.
  pubmed

第7章 レプチンによる糖・脂肪代謝調節作用

P.210 掲載の参考文献

• 1) Matsuzawa Y., Funahashi T., Nakamura T.:Molecular mechanism of metabolic syndrome X:contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci 1999; 892; 146-154.
  pubmed

• 2) Zhang Y., Proenca R., Maffei M. et al:Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372; 425-432.
  pubmed

• 3) Friedman J.M., Halaas J.L.:Leptin and the regulation of body weight in mammals. Nature 1998; 395; 763-770.
  pubmed

• 4) Pelleymounter M.A., Cullen M.J., Baker M.B. et al:Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269; 540-543.
  pubmed

• 5) Kamohara S., Burcelin R., Halaas J.L. et al:Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 1997; 389; 374-377.
  pubmed

• 6) Minokoshi Y., Haque, M. S., Shimazu T.:Microinjection of leptin into the ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats. Diabetes 1999; 48;287-291.
  pubmed

• 7) Haque M.S., Minokoshi Y., Hamai M. et al:Role of the sympathetic nervous system and insulin in enhancing glucose uptake in peripheral tissues after intrahypothalamic injection of leptin in rats. Diabetes 1999; 48; 1706-1712.
  pubmed

• 8) Minokoshi Y., Kim Y.B., Peroni O.D. et al:Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002; 415; 339-343.
  pubmed

• 9) Tartaglia L.A., Dembski M., Weng X. et al:Identification and expression cloning of a leptin receptor, OB-R. Cell 1995; 83; 1263-1271.
  pubmed

• 10) Lee G.H., Proenca R., Montez J.M. et al:Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996; 379; 632-635.
  pubmed

• 11) Takaya K., Ogawa Y., Isse, N. et al:Molecular cloning of rat leptin receptor isoform complementary DNAs--identification of a missense mutation in Zucker fatty fa/fa rats. Biochem Biophys Res Commun 1996; 225; 75-83.
  pubmed

• 12) Takaya K., Ogawa Y., Hiraoka J. et al:Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky rat. Nat Genet 1996; 14; 130-131.
  pubmed

• 13) Montague C.T., Farooqi I.S., Whitehead J.P.:Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387; 903-908.
  pubmed

• 14) Clement K., Vaisse C., Lahlou N.:A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998; 392; 398-401.
  pubmed

• 15) Vaisse C., Halaas J.L., Horvath C.M. et al:leptin activation of stat 3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat Genet 1996; 14; 95-97.

• 16) Banks W.A.:Leptin transport across the blood-brain barrier:implications for the cause and treatment of obesity. Curr Pharm Des 2001; 7; 125-133.
  pubmed

• 17) Harris R.B.:Leptin--much more than a satiety signal. Annu Rev Nutr 2000; 20; 45-75.
  pubmed

• 18) Shimizu Y., Nikami H., Saito M.:Sympathetic activation of glucose utilization in brown adipose tissue in rats. J Biochem 1991;110;688-392.
  pubmed

• 19) Morimoto A., Murakami N:[14C]deoxyglucose incorporation in to rat brain reginos during hypothalamic or peripheral thermal stimulation. Am J Physiol Regul Integr Comp Physiol 1985; 248; R84-R92.

• 20) Sudo M., Minokoshi Y., Shimazu T.:Ventromedial hypothalamic stimulation enhances peripheral glucose uptake in anesthetized rats. Am J Physiol Endocrinol Metab 1991; 24;E298-E303.

• 21) Minokoshi Y., Okano Y., Shimazu T.:Regulatory mechanism of the ventromedial hypothalamus in enhancing glucose uptake in skeletal muscles. Brain Res 1994; 649; 343-347.
  pubmed

• 22) DeFronzo R.A., Jacot E., Jequier E. et al:The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 1981;30;1000-1007.
  pubmed

• 23) Hynes W.G., Morgan D.A., Walsh S.A. et al:Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997; 100; 270-278.

• 24) Scarpace P.S., Matheny M., Pollock B.H. et al:Leptin increases uncoupling protein expression and energy expenditure. Am J Physiol Endocrinol Metab 1997; 273; E226-E230.

• 25) Elmquist J.K., Bjorbaek C., Ahima R.S. et al:Distribution of leptin receptor mRNA isoforms in the rat brain. J Com Neurol 1998;395;535-547.

• 26) Ogawa Y., Masuzaki H., Hosoda K. et al:Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. Diabetes 1999; 48; 1822-1829.
  pubmed

• 27) Shimomura I., Hammer R., Ikemoto S. et al:Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nautre 1999; 401; 73-76.

• 28) Lin C., Higginbotham A., Judd R.L. et al:Central leptin increases insulin sensitivity in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 2002; 282;E1084-E1091.

• 29) Oarl A.E., Simha V., Ruiz E. et al:Leptin-replacement therapy for lipodystrophy. N Eng J Med 2002; 8; 570-578.

• 30) Peterson K.F., Oral E.A., Dufour S. et al:Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002; 109; 1345-1350.

• 31) Halaas J.L, Gajiwaka K.S. Mafei M. et al:Weight reducing effects of the plasma protein encoded by he obese gene. Science 1995; 269; 543-546.

• 32) Haw J.J., Ghibaudi L., Compton D. et al:Intracerebroventricular injection of leptin increases thermogenesis and mobilizes fat metabolism in ob/ob mice. Horm Metab Res 1996; 28; 659-663.

• 33) Hardie D.G., Carling D.:The AMP-activated protein kinase. Fuel Gauge of the mammalian cell? Eur J Biochem 1997; 246; 259-273.
  pubmed

• 34) Hardie D.G., Carling D, Carlson M.:The AMP-activated/SNF1 protein kinase subfamily:metabolic sensors of the eukaryotic cell? Ann Rev Biochem 1998; 67;821-855.
  pubmed

• 35) Winder W.W., Hardie D.G.:AMP-activated protein kinase, a metabolic master switch:possible roles in type 2 diabetes. Am J Physiol Endocrinol Metab 1999; 277;E1-E10.

• 36) Winder W.W.:Energy-sensing and signaling by AMP-activated protein kinase in skeletal muscle. J Appl Physiol 2001; 91; 1017-1028.
  pubmed

• 37) Zhou G., Myers R., Li Y. et al:Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108; 1167-1174.
  pubmed

• 38) Yamauchi T., Kamon J., Minokoshi Y. et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8; 1288-1295.
  pubmed

• 39) Hardie D.G., Hawley S.A.:AMP-activated protein kinase:the energy charge hypothesis revisited. Bioessays 2001; 23; 1112-1119.
  pubmed

• 40) Daniel T., Carling D.:Expression and regulation of the AMP-activated protein kinase-SNF1 sucrose non-fermenting 1 kinase complexes in yeast and mammalian cells:studies using chimaeric catalytic subunits. Biochem J 2002; 363;167-174.

• 41) Fryer L.G., Parbu-Patel A., Carling D.:The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002; 277; 25226-25232.
  pubmed

• 42) Hayashi T., Jogen F.P., Wojtaszewski J.F.P.et al:Exercise regulation of glucose transport in skeletal muscle. Am J Physiol Endocrinol Metab 1997; 273; E1039-E1051.

• 43) Winder W.W., Hardie D.G.:Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am J Physiol Endocrinol Metab 1996; 270; E299-E304.

• 44) Musi N., Hayashi T., Fugii N. et al:AMP-activated protein kinase activity and glucose uptake in rat skeletal muscle. Am J Physiol Endocrinol Metab 2001; 280;E677-E684.

• 45) Wojtaszewski J.F., Nielsen P., Hansen B.F.:Isoform-specific and exercise intensity-dependent activation of 5'-AMP-activated protein kinase in human skeletal muscle. J Physiol Lond 2000; 528; 221-226.
  pubmed

• 46) Kurth-Kraczek J.E., Hirshman M.F., Goodyear L.J. et al:5' AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes 1999; 48; 1667-1671.

• 47) Hayashi T., Hirshman M.F., Kurth E.J. et al:Evidence for 5' AMP activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes 1998; 47; 1369-1373.
  pubmed

• 48) Ojuka E.O., Nolte L.A., Holloszy J.O.:Increased expression of GLUT-4 and hexokinase in rat epitrochlearis muscles exposed to AICAR in vitro. J Appl Physiol 2000; 88; 1072-1075.
  pubmed

• 49) Iglesias M.A., Ye J.M., Frangioudakis G. et al:AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant highfat-fed rats. Diabetes 2002; 51; 2886-2894.

• 50) Vavvas D., Apazidis A., Saha A.K. et al:Contraction-induced changes in acetyl-CoA carboxylase and 5'-AMP-activated kinase in skeletal muscle. J Biol Chem 1997; 272; 13256-13261.

• 51) Abu-Elheiga L, Matzuk M.M., Abo-Hashema K.A. et al:Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase. Science 2001; 291; 2613-2616.
  pubmed

• 52) Terada S., Goto M., Kato M. et al:Effects of low-intensity prolonged exercise on PGC-1 mRNA expression in rat epitrochlearis muscle. Biochem Biophys Res Commun 2002; 296; 350-354.
  pubmed

• 53) Mu J., Brozinick J.T. Jr., Valladares O. et al:A role for AMP-activated protein kinase in contraction-and hypoxia-regulated glucose transport in skeletal muscle. Mol Cell 2001; 7; 1085-1094.
  pubmed

• 54) Derave W., Ai H., Ihlemann J. et al:Dissociation of AMP-activated protein kinase activation and glucose transport in contracting slow-twitch muscle. Diabetes 2000; 49; 1281-1287.
  pubmed

• 55) Kishi K., Yuasa T., Minami A. et al:AMP-activated protein kinase is activated by the stimulations of Gq-coupled receptors. Biochem Biophys Res Commun 2000;276;16-22.
  pubmed

• 56) Oakes N.D., Kjellstedt A., Forsberg G-B. et al:Development and initial evaluation of a novel method for assessing tissue-specific plasma free fatty acid utilization in vivo using (R)-2-bromopalmitate tracer. J Lipid Res 1999; 40; 1155-1169.
  pubmed

• 57) Unger R.H., Zhou Y-T., Orci L. et al:Regulation of fatty acid homeostasis in cells:novel role of leptin. Proc Natl Acad Sci USA 1999; 96; 2327-2332.
  pubmed

• 58) Steinberg G.R., Rush J.W.E., Dyck D.J. et al:AMPK. expression and phosphorylation are increased in rodent muscle following chronic leptin treatment. Am J Physiol Endocrinol Metab 2002;284;E648-E654.

• 59) Muoio D.M., Dohm G.L., Fiedoreck F.T.Jr. et al:Leptin directly alters lipid partitioning in skeletal muscle. Diabetes 1997; 46; 1360-1363.

• 60) Zierath J.R., Frevert E.U., Ryder J.W. et al:Evidence against a direct effect of leptin on glucose transport in skeletal muscle and adipocytes. Diabetes 1998; 47;1-4.
  pubmed

• 61) Steinberg G.R., Parolin M.L., Heigenhauser G.J.F. et al:Leptin increases FA oxidation in lean but not obese human skeletal muscle:evidence of peripheral leptin resistance. Am J Physiol Endocrinol Metab 2002; 283; E187-E192.

第8章 運動・栄養と中枢性疲労

P.246 掲載の参考文献

• 1) 森谷敏夫: 筋疲労. 呼吸 1990; 9; 965-972.
  Medical*Online

• 2) Blomstrand E., Celsing F., Newsholme E.A.:Changes in plasma concentrations of aromatic and branched-chain amino acids during sustained exercise in man and their possible role in fatigue. Acta Physiol Scand 1988; 133; 115-121.
  pubmed

• 3) Blomstrand E., Perrett D., Parry-Billings M. et al:Effect of sutained exercise on plasma amino acid concentrations and on 5-hydroxytryptamine metabolism in six different brain regions in the rat. Acta Physiol Scand 1989; 136; 473-481.

• 4) Yamamoto T., Castell L. M., Botella J. et al:Changes in the albumin binding of tryptophan during postoperative recovery:a possible link with central fatigue? Brain Res Bull 1997; 43; 43-46.
  pubmed

• 5) Yamamoto T., Newsholme E.A.:Diminished central fatigue by inhibition of the L-system transporter for the uptake of tryptophan. Brain Res Bull 2000; 52; 35-38.

• 6) Bailey S.P., Davis J.M., Ahlborn, E.N.:Effect of increased brain serotonergic activity on endurance performance in the rat. Acta Physiol Scand 1992; 145:75-76.
  pubmed

• 7) Bailey S.P., Davis J.M., Ahlborn E.N.:Neuroendocrine and substrate response to altered brain 5-HT activity during prolonged exercise to fatigue. J Appl Physiol 1993; 74; 3006-3012.
  pubmed

• 8) Inoue K., Yamazaki H., Manabe Y. et al:Release of a substance that suppresses spontaneous motor activity in the brain by physical exercise. Physiol Behav 1998; 64; 185-190.

• 9) Matsumoto K., Ishihara K. Tanaka. et al:An adjustable-current swimming pool for the evaluation of endurance capacity of mice. J Appl Physiol 1996;81; 1843-1849.
  pubmed

• 10) Ueda H., Amano H., Shiomi H. et al:Comparison of the analgesic effects of various opioid pepteides by a newly devised intracisternal injection technique in conscious mice. Eur J Pharmacol 1979;56;265-268.
  pubmed

• 11) Inoue K., Yamazaki H., Manabe Y. et al:Transforming growth factor-beta activated during exercise in brain depresses spontaneous motor activity of animals. Relevance to central fatigue. Brain Res 1999;846;145-153.
  pubmed

• 12) Manabe Y., Yamazaki H., Fukuda C. et al:Suppression of S-methylglutathioneinduced tentacle ball formation by peptides and nullification of the suppression by TGF-beta in Hydra. Chem Senses 2000; 25; 173-180.
  pubmed

• 13) Hanai K., Kato H., Matsuhashi S. et al:Platelet protein, including plateletderived growth factor, specifically depress a subset of the multiple components of the response elicited by glutathione in Hydra. J Cell Biol 1987; 104; 1675-1681.
  pubmed

• 14) Hanai K., Oomura Y., Kai Y. et al:Central action of acidic fibroblast growth factor in feeding regulation. Am J Physiol 1989; 256; R217-R223.
  pubmed

• 15) Manabe Y., Yamazaki H., Fukuda C. et al:Hydra biological detection of biologically active peptides in rat cerebrospinal fluid. Brain Res Protcol 2000; 5; 312-317.

• 16) Torii K., Hanai K., Oosawa K. et al.:Activin A:Serum levels and immunohistochemical brain localization in rats given diets deficient in L-lysine or protein. Phsysiol. Behav. 1993; 54; 459-466.
  pubmed

• 17) Massague J.:The transforming growth factor-β. Annu Rev Cell Biol 1990; 597-641.

• 18) Massague J., Chen Y-G.:Controlling TGF-β signaling. Genes Develop. 2000; 14; 627-644.

• 19) Lyons R.M., Gentry L.E., Purchio A.F. et al:Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 1990; 110; 1361-1367.
  pubmed

• 20) Yu Q., Stamenkovic I.:Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Develop. 2000; 14; 163-176.

• 21) Ribeiro S.M.F., Poczatek M., Schultz-Cherry S. et al.:The activation sequence of thrombospondin-1 interacts with the latancy-associated peptide to regulate activation of latent transforming growth factor-β. J Biol Chem 1999;274; 13586-13593.

• 22) Annes J.P., Rifkin D.B., Munger J.S.:The integrin a Vβ6 binds and activates latent TGFb3. FEBS Lett. 2002; 511; 65-68.

• 23) Derynck R., Feng X-H.:TGF-β receptor signaling. Biochim Biophys Acta 1997; 1333; F105-F150.

• 24) Arai M., Yamazaki H., Inoue K. et al.:Effects of intracranial injection of transforming growth factor-beta relevant to central fatigue on the waking electroencephalogram of rats. Comparison with effects of exercise. Prog Neuro-Psychopharmacol Biol Psychiatry 2002; 26; 307-312.

• 25) Klimesch W.:EEG alpha and theta oscillations reflect cognitive and memory performance, a review and analysis. Breain Res Rev 1999;29;169-195.
  pubmed

• 26) Yamazaki H., Arai M., Matsumura S. et al:Intracranial administration of transforming growth factor-beta 3 increases fat oxidation in rats. Am J Physiol Endocrinol Metab 2002;283;E536-E544.
  pubmed

• 27) Short K. R., Sedlock D.A.:Excess postexercise oxygen consumption and recovery rate in trained and untrained subjects. J Appl Physiol 1997; 83; 153-159.
  pubmed

• 28) Saito M., Ishihara K., Onuki K., et al:Effects of Nanpao, a mixture of 31 Chinese crude drugs, on increasing endurance exercise performance of swimming mice.(in Japanese). Natural Medicine 1998; 52; 14-21.